News about Global Pharma

Solvent Direct Launches Cannabis Extraction Safety Program with LSI and CARMA365

Solvent Direct has officially partnered with the Laboratory Safety Institute (LSI) and CARMA365 Insurance to launch a powerful safety and certification program tailored specifically for cannabis extraction professionals.

Global Pharma | 03/05/2025 | By Manvi |  237

USMGC Leases Ohio Facility to Finalize All-American Glove Supply Chain

This critical move marks the final phase in USMGC's mission to build and secure a 100 percent American-made medical and surgical glove supply chain—free from reliance on China or any foreign supplier.

Global Pharma | 03/05/2025 | By Manvi |  396

Alembic Pharmaceuticals Secures USFDA Approval for Ticagrelor Tablets

Alembic Pharmaceuticals has received USFDA final approval for Ticagrelor Tablets, 90 mg, and tentative approval for 60 mg.

Global Pharma | 03/05/2025 | By Manvi |  357

SMS Pharma's Vizag Plant Secures WHO Geneva Prequalification Approval

SMS Pharmaceuticals’ Unit VII facility in Visakhapatnam has received WHO Geneva prequalification, boosting its global regulatory credentials and market access for Anti-Retroviral APIs.

Global Pharma | 03/05/2025 | By Manvi |  442

FaceHeart Corporation Gets FDA 510(k) Clearance for FaceHeart Vitals

FaceHeart Corporation (FaceHeart), an AI health tech company, has received another FDA 510(k) clearance for FaceHeart Vitals™, its contactless video-based vital sign solution.

Global Pharma | 02/05/2025 | By Manvi |  508

Winter Park Chiropractor Introduces EXOMIND Brain Stimulation for Mental Health and Emotional Relief

Individuals suffering from depression, stress or mental fog can find relief at Winter Park Chiropractor, the office of Dr. Andrew Hull. This state-of-the-art chiropractic clinic is now offering EXOMIND, a cutting-edge treatment enhancing mental health and emotional regulation through non-invasive brain stimulation.

Global Pharma | 02/05/2025 | By Manvi |  313

S&E bio Secures Korea's First Approval for Exosome-Based Therapy Clinical Trial

S&E bio Co. Ltd. has received Korea's Ministry of Food and Drug Safety (MFDS) approval to begin Phase 1b clinical trial of an exosome-based therapy, SNE-101. The exosomes carry therapeutic microRNAs designed to enhance neuroregeneration.

Global Pharma | 02/05/2025 | By Manvi |  311

RoosterBio, Thermo Fisher Scientific Partner to Advance Cell and Exosome Therapy Manufacturing

RoosterBio has partnered with Thermo Fisher Scientific to accelerate the development and manufacturing of advanced cell and exosome therapies for degenerative diseases, combining hMSC expertise with GMP manufacturing capabilities.

Global Pharma | 02/05/2025 | By Manvi |  257

Gland Pharma Secures USFDA Approval for Latanoprostene Bunod Ophthalmic Solution

Gland Pharma has received USFDA approval for its generic version of Latanoprostene Bunod Ophthalmic Solution, 0.024 percent, securing first-to-file status with 180 days of generic drug exclusivity.

Global Pharma | 01/05/2025 | By Manvi |  464

Strides Pharma Secures USFDA Approval for Celecoxib Capsules

Strides Pharma has announced that its Singapore-based step-down subsidiary has received USFDA approval for Celecoxib Capsules (100 mg, 200 mg, and 400 mg), a generic equivalent of Celebrex, strengthening its presence in the anti-inflammatory segment.

Global Pharma | 01/05/2025 | By Manvi |  262